ATN-658 is a first in class therapeutic which is a humanized monoclonal antibody to the urokinase plasminogen activator receptor (uPAR). uPAR is a preclinically well validated target and ATN-658 targets it in a novel way. ATN-658 has potential for broad spectrum cancer use, and it targets multiple cell types within a tumor.
ATN-658 is expected to have broad spectrum activity against a variety of tumor types, including, but not limited to ovarian, prostate, breast, pancreatic, colon, and renal cell cancer. It has robust anti-tumor activity in numerous preclinical tumor models: effective as a monotherapy, and also enhances the activity of several widely used chemotherapeutics. No Known uPAR interventional strategy has demonstrated comparable in vivo activity. ATN-658 will shortly be entering Phase I.